Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Master Study to Assess the Safety and Efficacy of PM54 in Combination With Cytotoxic and Targeted Agents for the Treatment of Advanced Solid Tumors

NCT07839819 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT07839819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07839819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Master Study to Assess the Safety and Efficacy of PM54 in Combination With Cytotoxic and Targeted Agents for the Treatment of Advanced Solid Tumors
Lead sponsor
PharmaMar
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 12, 2026
Completion date
November 27, 2029
Enrollment
231 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor